Stock Price & Analysis

Buy AXSM stock as it has a Strong Buy rating with a $164.38 average price target, representing significant upside potential. The stock's positive momentum, driven by strong commercial performance and strategic growth initiatives, supports further growth.

Price Prediction for AXSM Stock in 2025

Based on analyst consensus and recent developments, Axsome Therapeutics (AXSM) is predicted to reach a price target of $200 by 2025. This forecast is supported by the company's strong commercial performance, particularly with Auvelity, and its robust pipeline, including Symbravo and AXS-05. Analysts highlight the resolution of the Teva patent litigation and upcoming Phase 3 data readouts as key catalysts for growth.

The S1 support level for AXSM Stock is $117.75 ,The R1 resistant level for AXSM Stock is $127.3.

As of the end of day on 2025-03-24, the price of AXSM Stock was $126.66.

The target price for AXSM Stock according to analyst rating is 171.29, with the highest price target at 212.00 and the lowest at 117.00. Analysts have a Strong Buy rating on AXSM Stock overall.

The market cap of AXSM is $6.3B.

Analysis and Insights

AXSM may appear overvalued due to its high price-to-sales (PS) ratio of 26.30, which is significantly above industry averages, suggesting high market expectations for future growth. However, the stock is supported by strong analyst sentiment, with an average price target of $164.38, indicating a 32% upside potential. Recent positive developments, such as the settlement of patent litigation and promising pipeline progress, justify the premium valuation. While the stock is expensive, it is not yet overvalued given its growth prospects and analyst confidence.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

AXSM stock is predicted to reach approximately $200 by 2030, driven by its robust product pipeline and extended market exclusivity for Auvelity. The company's strong revenue growth and pipeline expansion position it for long-term appreciation.

AXSM has a total of 545 employees.